Received May 10, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | IM / LA |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | LA |
Redness/red dots on arm; Swelling; Itching; Fever; Sickness; This non-serious case was reported by a consumer via call center representative and described the occurrence of erythema of extremities in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 16-APR-2026, the patient received the 2nd dose of Shingrix (left arm). In APR-2026, less than 2 weeks after receiving Shingrix, the patient experienced erythema of extremities (Verbatim: Redness/red dots on arm), swelling (Verbatim: Swelling), pruritus (Verbatim: Itching), fever (Verbatim: Fever) and sickness (Verbatim: Sickness). The outcome of the erythema of extremities, swelling, pruritus, fever and sickness were unknown. It was unknown if the reporter considered the erythema of extremities, swelling, pruritus, fever and sickness to be related to Shingrix. It was unknown if the company considered the erythema of extremities, swelling, pruritus, fever and sickness to be related to Shingrix. Additional Information: GSK Receipt Date: 29-APR-2026 The batch number was not provided upon follow up with the reporter.